Ocugen, Inc. (OCGN)
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Address
11 GREAT VALLEY PARKWAY
MALVERN, PA 19355
Founded
2013
Number of Employees
65
Website
http://www.ocugen.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)